ACER - Acer Therapeutics GAAP EPS of -$0.54 misses by $0.17
2023-03-27 17:02:39 ET
- Acer Therapeutics press release ( NASDAQ: ACER ): Q4 GAAP EPS of -$0.54 misses by $0.17 .
- Ended Q4 2022 with $2.3 million in cash and cash equivalents. Acer believes its cash and cash equivalents available at December 31, 2022, together with the gross proceeds of $7.0 million from a second term loan with SWK Funding LLC which closed on January 31, 2023, $4.1 million from Acer’s ATM facility subsequent to December 31, 2022, and $2.7 million from a sale of securities which closed on March 24, 2023, will be sufficient to fund Acer’s anticipated operating and capital requirements into the middle of Q2 2023.
- Shares +1.57% AH.
For further details see:
Acer Therapeutics GAAP EPS of -$0.54 misses by $0.17